BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Religare maintains buy on Natco Pharma
Second quarter profit of the company was broadly in-line with estimates. Religare values the base business of Natco Pharma at 18 times its FY18 estimated earnings per share and the filing pipeline at Rs 437 per share.